Cargando…
Post Covishield (ChAdOx1 nCoV-19) Vaccination: New Onset Focal Segmental Glomerulosclerosis Resistant to Steroid and Calcineurin Inhibitor
With the ongoing mass COVID vaccination program, various case reports link the COVID-19 vaccines with heightened off-target immune responses leading to de novo development or relapse of various glomerular diseases. Very few glomerular diseases (totally nine published cases to date) have been reporte...
Autores principales: | Jha, Vijoy Kumar, Akal, Ramanjit Singh, Sharma, Alok, Mahapatra, Debasish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365003/ https://www.ncbi.nlm.nih.gov/pubmed/35967524 http://dx.doi.org/10.4103/ijn.ijn_23_22 |
Ejemplares similares
-
Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
por: Devi, Leimapokpam Sumitra, et al.
Publicado: (2022) -
Vaccination-associated immune thrombocytopenia possibly due to ChAdOx1 nCoV-19 (Covishield) coronavirus vaccine
por: Sivaramakrishnan, Prakash, et al.
Publicado: (2022) -
Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study
por: Singh, Amandeep, et al.
Publicado: (2022) -
Serological immune response following ChAdOx1 nCoV-19 vaccine (Covishield) in patients with liver cirrhosis
por: Katiyar, Harshita, et al.
Publicado: (2022) -
Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis
por: Goel, Amit, et al.
Publicado: (2022)